William C. Ports

Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial

Robert Bissonnette, Ana B. Pavel, Aisleen Diaz et al. · Journal of Allergy and Clinical Immunology · 2019 · 124 citations · Full text

Medicine, Dermatology, Pharmacology +14

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

Kim Papp, Robert Bissonnette, Melinda Gooderham et al. · BMC Dermatology · 2016 · 98 citations · Full text

Medicine, Dermatology, Pharmacology +11

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)

Joel Schlessinger, Julie S. Shepard, Richard Gower et al. · American Journal of Clinical Dermatology · 2020 · 89 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study

Jianzhong Zhang, Tsen‐Fang Tsai, Min‐Geol Lee et al. · Journal of Dermatological Science · 2017 · 86 citations · Full text

Medicine, Dermatology, Pharmacology +6

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies

Peter Nash, Laura C. Coates, Roy Fleischmann et al. · Rheumatology and Therapy · 2018 · 49 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15